Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $1.5 million.

  • Cue Biopharma's Share-based Compensation fell 315.86% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 2256.66%. This contributed to the annual value of $6.8 million for FY2024, which is 1630.81% down from last year.
  • As of Q3 2025, Cue Biopharma's Share-based Compensation stood at $1.5 million, which was down 315.86% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Share-based Compensation ranged from a high of $3.3 million in Q3 2021 and a low of $1.3 million during Q2 2025
  • Over the past 5 years, Cue Biopharma's median Share-based Compensation value was $2.1 million (recorded in 2022), while the average stood at $2.1 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 3036.23% in 2021, then tumbled by 3653.14% in 2022.
  • Cue Biopharma's Share-based Compensation (Quarter) stood at $3.0 million in 2021, then fell by 29.0% to $2.1 million in 2022, then decreased by 1.89% to $2.1 million in 2023, then decreased by 24.61% to $1.6 million in 2024, then decreased by 1.86% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.